The board of directors of the Racing Medication and Testing Consortium (RMTC) held a regular meeting Sept.17 in Denver, Colo. Phil Langley, president of the US Trotting Association (USTA), and Mike Tanner, USTA CEO, attended the meeting representing harness racing.
The RMTC board voted to authorize the RMTC's Scientific Advisory Committee to explore whether the scientific research will support separate medication rules for Standardbreds in regard to the withdrawal times for clenbuterol and intra-articular corticosteroids at the request of the United States Trotting Association.
The USTA and some Standardbred racing leaders have expressed concern that because Standardbreds race more frequently than Thoroughbreds and thus have post-race tests more frequently, withdrawal times recommended by RMTC for clenbuterol and intra-articular corticosteroids would effectively prohibit the use of those therapeutic medications unless a horse was sidelined from racing for several weeks.
The RMTC board also took the following actions:
The RMTC consists of 24 racing industry stakeholders and organizations that represent Thoroughbred, Standardbred, American Quarter Horse and Arabian racing. The organization works to develop and promote uniform rules, policies and testing standards at the national level; coordinate research and educational programs that seek to ensure the integrity of racing and the health and welfare of racehorses and participants; and protect the interests of the racing public.
For additional information, visit the RMTC website atrmtcnet.com or contact Hallie Lewis, RMTC director of communications, at (859) 224-2848. (with files from RMTC)